APA

Boyko A. N., Bosenko L. P., Vasilovskiy V. V., Volkova L. I., Zakharova M. N., Kotov S. V., Lekomtseva E. V., Negrich T. I., Parshina E. V., Patrusheva O. P., Prokopenko S. V., Sazonov D. V., Timchenko L. V., Trinitatskiy Y. V., Khabirov F. A., Khavunka M. Y., Chichanovskaya L. V., Sherman M. A., Ivanov R. A., Lin'kova Y. N., Stukalina E. Y., Zinkina-Orikhan A. V. & Obukhova I. G. (20190826). [Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a]. : Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Chicago

Boyko A N, Bosenko L P, Vasilovskiy V V, Volkova L I, Zakharova M N, Kotov S V, Lekomtseva E V, Negrich T I, Parshina E V, Patrusheva O P, Prokopenko S V, Sazonov D V, Timchenko L V, Trinitatskiy Yu V, Khabirov F A, Khavunka M Ya, Chichanovskaya L V, Sherman M A, Ivanov R A, Lin'kova Yu N, Stukalina E Yu, Zinkina-Orikhan A V and Obukhova I G. 20190826. [Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a]. : Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Harvard

Boyko A. N., Bosenko L. P., Vasilovskiy V. V., Volkova L. I., Zakharova M. N., Kotov S. V., Lekomtseva E. V., Negrich T. I., Parshina E. V., Patrusheva O. P., Prokopenko S. V., Sazonov D. V., Timchenko L. V., Trinitatskiy Y. V., Khabirov F. A., Khavunka M. Y., Chichanovskaya L. V., Sherman M. A., Ivanov R. A., Lin'kova Y. N., Stukalina E. Y., Zinkina-Orikhan A. V. and Obukhova I. G. (20190826). [Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a]. : Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

MLA

Boyko A N, Bosenko L P, Vasilovskiy V V, Volkova L I, Zakharova M N, Kotov S V, Lekomtseva E V, Negrich T I, Parshina E V, Patrusheva O P, Prokopenko S V, Sazonov D V, Timchenko L V, Trinitatskiy Yu V, Khabirov F A, Khavunka M Ya, Chichanovskaya L V, Sherman M A, Ivanov R A, Lin'kova Yu N, Stukalina E Yu, Zinkina-Orikhan A V and Obukhova I G. [Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a]. : Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 20190826.